very_low

The Expert Group recommended that the Genotype MTBDRsl assay cannot be used as a replacement
test for conventional phenotypic DST.

The GRADE evidence assessment confirmed that the quality of evidence for
commercial serodiagnostic tests was very low, with harms/risks far outweighing any potential benefits. It is therefore recommended that these tests should not be used
in individuals suspected of active pulmonary or extra-pulmonary TB, irrespective of their HIV status.

Screening for active TB on broader indications (for example in all people
diagnosed with diabetes, regardless of symptoms) should be explored
as part of the research agenda for improved TB diagnosis among people
with diabetes.

Establish and provide adequate financial resources for prevention, treatment, care and support programmes to prevent the occupational or non-occupational transmission of HIV and TB among health workers.

During the continuation phase of treatment, thrice-weekly regimens can be considered
for children known to be HIV-uninfected living in settings with well-established
directly-observed therapy (DOT).

Children with proven or suspected pulmonary tuberculosis or tuberculous meningitis
caused by multiple drug-resistant bacilli can be treated with a fluoroquinolone in the
context of a well-functioning MDR-TB control programme and within an appropriate
MDR-TB regimen. The decision to treat should be taken by a clinician experienced in
managing paediatric tuberculosis.

WHO recommends against using LF-LAM to assist in the diagnosis of active TB in HIV-positive adults, adolescents and children: without TB symptoms and with a CD4 cell count of 100–200 cells/mm3.

WHO recommends against using LF-LAM to assist in the diagnosis of active TB in HIV-positive adults, adolescents and children: without TB symptoms and unknown CD4 cell count or without TB symptoms and CD4 cell count greater than or equal to 200 cells/mm3.

WHO recommends against using LF-LAM to assist in the diagnosis of active TB in HIV-positive adults, adolescents and children: without assessing TB symptoms.

WHO suggests using LF-LAM to assist in the diagnosis of active TB in HIV-positive adults, adolescents and children: irrespective of signs and symptoms of TB and with a CD4 cell count of less than 100 cells/mm3.